Without effective collaboration, critical protection can be compromised, risks can increase, and the potential for successful commercialization can be diminished. Managing conflicts between scientific innovation and patentability requires a careful balance between pushing the boundaries of scientific discovery and meeting the rigid legal criteria for obtaining a patent.
Whether your organisation is focused on discovering new therapeutics, developing generics, or exploring drug repurposing, the latest whitepaper by CAS – Synergizing Innovation and Protection outlines how this synergy must span the entire drug development process - from initial investment planning and target identification all the way to clinical development and commercialisation.
Download the whitepaper now and gain the insights you need to protect innovation >>>
The key strategies from this special report include:
Download the report to unlock these strategies >>>
For more information, contact:
Graeme Cathie
Publisher
World IP Review and Life Sciences IP Review
Direct Tel: +44 203 301 8228
Email:
gcathie@newtonmedia.co.uk
Download your copy of the whitepaper here!
Enter your details below and you’ll immediately receive a copy of the report straight to your inbox.
This special report is distributed by Life Sciences IP Review and produced and sponsored by CAS. By registering to view the publication, you agree to share your contact information with both Life Sciences IP Review and CAS. Full details of Life Sciences IP Review privacy policy can be found here, and CAS's privacy policy can be found here.
Sponsored by
